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Abstract
Background: There is currently a requirement for antiviral therapies capable of protecting against
infection with Venezuelan equine encephalitis virus (VEEV), as a licensed vaccine is not available for
general human use. Monoclonal antibodies are increasingly being developed as therapeutics and are
potential treatments for VEEV as they have been shown to be protective in the mouse model of
disease. However, to be truly effective, the antibody should recognise multiple strains of VEEV and
broadly reactive monoclonal antibodies are rarely and only coincidentally isolated using classical
hybridoma technology.
Results:  In this work, methods were developed to reliably derive broadly reactive murine
antibodies. A phage library was created that expressed single chain variable fragments (scFv)
isolated from mice immunised with multiple strains of VEEV. A broadly reactive scFv was identified
and incorporated into a murine IgG2a framework. This novel antibody retained the broad reactivity
exhibited by the scFv but did not possess virus neutralising activity. However, the antibody was still
able to protect mice against VEEV disease induced by strain TrD when administered 24 h prior to
challenge.
Conclusion: A monoclonal antibody possessing reactivity to a wide range of VEEV strains may be
of benefit as a generic antiviral therapy. However, humanisation of the murine antibody will be
required before it can be tested in humans.
Crown Copyright © 2009
Background
The  Alphavirus  Venezuelan equine encephalitis virus
(VEEV) is a single stranded, positive-sense RNA virus
maintained in nature in a cycle between small rodents and
mosquitoes [1]. Six serogroups (I-VI) are currently recog-
nised within the VEEV complex. Spread of epizootic
strains of the virus (IA/B and IC) to equines leads to a high
viraemia followed by lethal encephalitis and lateral
spread to humans. In the human host, VEEV can produce
a febrile illness followed in a small proportion of cases by
severe encephalitis. Equine epizootics may lead to wide-
spread outbreaks of human encephalitis involving thou-
sands of cases and hundreds of deaths [1]. Viruses in other
serogroups do not appear to be equine-virulent and per-
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sist in a stable enzootic cycle. Natural transmission of
enzootic viruses to humans is rare but may be associated
with severe disease [2].
Epizootic VEEV can be controlled by the immunisation of
equines with the attenuated vaccine strain TC-83.
Although TC-83 is solidly protective in equines and has a
good safety record [2], in humans it fails to produce pro-
tective immunity in up to 20% of recipients and is reac-
togenic in around 20% of recipients [3]. There have also
been reports that the vaccine is potentially diabetogenic
[4] and teratogenic [5]. Consequently, TC-83 is no longer
available for human use in Europe and has limited avail-
ability in the U.S.A [6]. Both epizootic and enzootic
strains of VEEV are infectious for humans by the airborne
route and have been responsible for a number of labora-
tory infections [7].
In the absence of a suitable vaccine, antiviral therapies
which are effective in prophylaxis and treatment of VEEV
infection are required. There is evidence to suggest that
protection against VEEV requires high antibody levels
and, in the case of airborne infection, the presence of anti-
body on the mucosal surface of the respiratory tract [8].
Previous studies in the mouse model have shown that
monoclonal antibodies can protect against VEEV and are
effective against disease even when administered 24 h
after exposure [8-10]. Although broadly reactive murine
monoclonal antibodies have been coincidentally isolated
using classical hybridoma technology [10], in general
monoclonal antibodies have narrow specificities which
limit their use as antiviral therapies. We set out to develop
a capability to reliably derive new broadly reactive anti-
bodies in the mouse, which would have the potential to
protect humans against exposure to a range of VEEV
strains.
Results
Generation of a novel VEEV-specific monoclonal antibody
Balb/c mice were initially immunised with VEEV vaccine
strain TC-83, which is known to provide solid protection
against a large challenge dose of most, if not all, mouse-
virulent VEEV strains. Two doses of a mixture of represent-
ative viruses from subtypes IA/B, IC, ID, IE, IF, II, IIIA, IV,
V and VI were then administered to the immune mice on
days 14 and 21. The anti-VEEV immune response was
assessed on day 28 (end-point titre greater than 1:500
000) and the spleens removed for extraction of RNA and
conversion to cDNA. This was used to create a phage
library expressing single chain variable fragments (scFv)
which was enriched for antigen-specific scFv by two
rounds of panning with antigen from VEEV strain TC-83.
Individual phagemid clones were then tested for reactivity
to strain TC-83 by ELISA and positive clones were assessed
for uniqueness by analysing restriction digest patterns.
Eight unique clones were sequenced and compared at the
amino acid level for homology. A low level of homology
was found between the scFv sequences indicating that the
response to VEEV is not oligoclonal. Six of the unique
clones were tested by ELISA for reactivity to multiple VEEV
strains (Figure 1). Phagemid clone #12 is not shown in
Figure 1 as it had a high level of reactivity to the negative
control antigen and therefore conclusions can not be
made with regard to VEEV reactivity. Phagemid clone #37
showed the highest level of activity to the widest range of
strains and a low reactivity to the negative control antigen.
It was therefore chosen for conversion into a murine
IgG2a kappa antibody, which was designated CUF37-2a.
Murine IgG2a was chosen as the framework as it has
equivalent biological and functional activities to human
IgG1. The amino acid sequence of the scFv incorporated
into CUF37-2a is shown in Figure 2.
Activity of CUF37-2a in ELISA and Neutralisation assays
In order to ensure that the range of VEEV reactivity had
been retained during the incorporation of scFv from
phagemid clone #37 into CUF37-2a, the antibody was
tested in an ELISA using antigens from multiple strains
(Figure 3). High levels of reactivity were seen for all
strains, with the exception of AG80 (subtype VI) but
phagemid clone #37 did not react well with this strain
either (Figure 1). However, when the ability of the anti-
body to neutralise virus infectivity was tested, it was found
that CUF37-2a was not able to neutralise virus from sub-
types IA/B (strain TrD), II (strain Fe37c) or III (strain
BeAn8) (results not shown).
Glycoprotein specificity
VEEV has two major glycoproteins (E2 and E1) that occur
on the virus surface as a heterodimer. Antibody reactivity
to either protein may be associated with protection
against virus challenge. When tested, CUF37-2a reacted
with cells expressing the E2 glycoprotein but not with cells
expressing the E1 glycoprotein (Figure 4), indicating that
the antibody is specific for the viral E2 protein rather than
the E1 protein. As expected, the E2-specific antibody
(1A3B7) and E1-specific antibody (3B2A9) reacted with
cells expressing the appropriate glycoprotein (Figure 4).
Passive protection
Previous work has demonstrated that monoclonal anti-
bodies which possess virus neutralising activity are effec-
tive at protecting mice from VEEV challenge [10].
However, protection in vivo is not necessarily associated
with the ability of antibodies to neutralise virus. Func-
tions of the Fc region of the antibody also play a role, prin-
cipally the capacity to bind to macrophage Fc receptors
[10,11]. It was therefore decided to test the ability of
CUF37-2a to protect mice against VEEV strain TrD (sub-
type IA/B).Virology Journal 2009, 6:206 http://www.virologyj.com/content/6/1/206
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In three independent experiments (using the same stock
of virus for challenge), the ability of a range of doses of
CUF37-2a to protect against VEEV disease was assessed
(Figure 5). Untreated mice did not survive the challenge
dose and the median time to death was six days. The
enhanced survival observed when mice were treated with
CUF37-2a was statistically significant compared to
untreated mice (P = 0.0043, P = 0.0001 and P < 0.0001
with 5, 50 and 100 μg CUF37-2a respectively). The
increases in survival rates observed when a larger dose of
antibody was administered to mice was not significant (P
= 0.1139), although surviving mice treated with 50 or 100
μg CUF37-2a showed no clinical signs of infection
whereas all mice treated with 5 μg CUF37-2a exhibited
some clinical signs. However, it was determined by regres-
sion analysis that the relationship between survival and
antibody concentration was significant (P = 0.0371).
From the regression equation, 50% protection was
achieved with a dose of 9.15 μg CUF37-2a.
The sera of mice that had been treated with 100 μg
CUF37-2a were tested for VEEV-specific IgG1 by ELISA.
The levels of IgG1 were measured in order to distinguish
the response induced by the murine immune system and
CUF37-2a, which is IgG2a. All mice generated an immune
response to VEEV (mean 232.39 ng/ml, 95% confidence
interval 106.94 ng/ml, n = 8). However, it is not known if
this response had a role to play in the survival of mice
treated with CUF37-2a. The brains of mice that had been
treated with 100 μg CUF37-2a were also harvested and
tested for the presence of virus. No virus was detectable in
any of the brains (n = 8) whereas brains that were har-
vested from untreated mice culled 7 days after challenge
(n = 2) contained 2.967 × 107pfu and 5.368 × 107pfu.
Discussion
Effective antiviral therapies are required for VEEV as a vac-
cine is not generally available. Monoclonal antibodies are
finding increasing application for therapies against other
viruses [12] and they have been shown to be protective in
the mouse model of VEEV disease [8-10]. This is the first
demonstration of a monoclonal antibody, specifically
designed to be reactive against multiple VEEV strains,
Reactivity of phagemid clones to a wide range of VEEV strains Figure 1
Reactivity of phagemid clones to a wide range of VEEV strains. Supernatants from phagemid clones, containing equiv-
alent bacteriophage titres, were tested by ELISA using antigen prepared from VEEV strains TC-83, TrD, P676, 3880, Mena II, 
78V, Fe37c, BeAn8, Pixuna, CaAr508 and AG80 (subtypes IA/B, IA/B, IC, ID, IE, IF, II, IIIA, IV, V and VI respectively). Negative 
control antigen was prepared from cells that had been mock infected. n = 3 for all data points.
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being created using phage display technology and molec-
ular biology techniques.
The purpose of this work was to create a novel antibody
able to react with a wide range of VEEV strains which
would have potential as an antiviral therapy for human
use. Murine antibodies generally require molecular
manipulation to make them similar to human antibodies
(a process known as humanisation) before they can be
used as therapeutics in humans. Human VEEV-specific
monoclonal antibodies, produced by phage display tech-
nology [13], have not yet proved to be broadly cross-reac-
tive and the hyperimmunisation regimes necessary to
ensure a high frequency of broadly reactive antibodies
would not be ethical in humans. We therefore believe that
developing broadly reactive antibodies in mice and then
subjecting the antibodies to humanisation procedures is
more likely to lead to the development of an anti-VEEV
therapy suitable for humans.
For therapeutic applications, antibodies with virus neu-
tralising activity have usually been selected. As CUF37-2a
was not able to neutralise the infectivity of multiple sub-
types (IA/B, II or III), the antibody was only tested against
VEEV strain TrD. A single dose successfully protected mice
when administered 24 h prior to challenge. The protective
activity of CUF37-2a may have been due to the ability of
the antibody to abort the infection, to prevent spread of
virus to the brain or to delay virus replication, giving the
host immune response time to respond and control virus
infection. It was determined that 50% of mice would be
protected from a subcutaneous VEEV challenge when a
dose of 9.15 μg of CUF37-2a was administered 24 h prior
to challenge. Previous work [8,10] has shown that other
VEEV-specific monoclonal antibodies (1A4A-1, 3B2A-9
and 1A3B-7) protect 50% of Balb/c mice against an air-
borne challenge at doses of 8, 10 and 10 μg respectively.
Although CUF37-2a was not neutralising, protection
induced by this antibody, which was generated using a
phage library and molecular incorporation into an IgG2a
framework, seems to compare favourably to protection
induced by antibodies generated using classical hybrid-
oma technology (1A4A-1, 3B2A-9 and 1A3B-7). Humani-
sation of CUF37-2a will be essential if this antibody is to
find use as an antiviral in humans and these data suggest
that CUF37-2a may be a suitable candidate.
The pathogenesis of VEEV disease in mice and humans is
believed to be similar and in mice the virus usually enters
the central nervous system two or three days after periph-
Annotated amino acid sequence of scFv CUF37-2a Figure 2
Annotated amino acid sequence of scFv CUF37-2a. Nucleotide sequences were edited and translated using Lasergene 
software http://www.dnastar.com. The Pel B leader peptide to direct secretion of the scFv to the periplasm of E. coli host cells 
during heterologous expression is underscored with a dotted line. The cleavage point of this signal peptide is indicated with a 
block arrow. The presence of a Flag-tag antibody at the N-terminus of the protein is shown with a double underline. The poly-
glycine linker joining the VL and VH chains of the scFv is underlined with a single solid line. The Framework Regions (FR) and 
Complementarity Determining Regions (CDR) within the scFv sequence are indicated with arrows and with shading respec-
tively.
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eral inoculation [14]. After airborne infection there is the
additional possibility that virus may multiply in the olfac-
tory neuroepithelium and thereby gain direct access to the
olfactory nerve and brain. Thus, there is limited time
available for antivirals to be administered after exposure
to VEEV if they are to be used as therapeutics rather than
as prophylactics. In previous work, monoclonal antibod-
ies used as post-exposure antiviral therapies for VEEV were
only effective when administered 24 h after infection [8,9]
and not at 48 h [9] or 72 h [8]. Antivirals therefore need
to be administered quickly enough after infection to pre-
vent VEEV from accessing the brain or, alternatively, anti-
virals that are able to cross the blood-brain barrier are
required to block viral replication in the brain. Previously,
intraperitoneally administered monoclonal antibodies
have been shown to have little effect on established VEEV
infection of the brain [8] indicating that specialised deliv-
ery systems will be necessary to transport them into the
brain in order to inhibit established infections and pre-
vent encephalitis.
Conclusion
In the present study, we have developed methods that use
phage display technology in order to generate a mono-
clonal antibody with activity against a wide range of VEEV
strains. The ability to reliably derive broadly reactive anti-
bodies in the mouse is a significant improvement on
depending on their chance isolation when classical hybri-
doma technology is used. Monoclonal antibodies are
attractive candidates for new antiviral therapies for VEEV
and an antibody capable of reacting with multiple strains
would be the most desirable. However, before administra-
tion to humans, it is likely that an antibody generated in
the mouse would have to undergo a degree of humanisa-
tion so that adverse immune reactions are avoided.
Materials and methods
Cells and viruses
The L929 (murine fibroblast), HEK 293 (human kidney)
and Vero (simian kidney) cell lines (European Collection
of Animal Cell Cultures, U.K.) were propagated by stand-
ard methods using the recommended culture media.
Stocks of VEEV vaccine strain TC-83 were propagated
from a vial of vaccine originally prepared for human use
(National Drug Company, Philadelphia, U.S.A.). Strains
of VEEV from serogroups IA/B (Trinidad donkey; TrD), IC
(P676), ID (3880), IE (Mena II), IF (78V), II (Fe37c), IIIA
(BeAn8), IV (Pixuna), V (CaAr508) and VI (AG80) were
kindly supplied by Dr. R.E. Shope (University of Texas
Medical Branch, U.S.A.). Virulent virus stocks were pre-
pared and the titre determined as described by Phillpotts
[10]. All work with virulent VEEV was carried out under
Reactivity of CUF37-2a to multiple VEEV strains Figure 3
Reactivity of CUF37-2a to multiple VEEV strains. CUF37-2a (20 μg/ml) was tested by ELISA using antigen prepared 
from VEEV strains TC-83, TrD, P676, 3880, Mena II, 78V, Fe37c, BeAn8, Pixuna, CaAr508 and AG80 (subtypes IA/B, IA/B, IC, 
ID, IE, IF, II, IIIA, IV, V and VI respectively). Negative control antigen was prepared from cells that had been mock infected. n = 
6 for all data points, 95% confidence intervals are shown.
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U.K. Advisory Committee on Dangerous Pathogens Level
3 containment.
Generation of a VEEV-reactive scFv phage library and 
conversion of one clone into a monoclonal antibody
Balb/c mice (7-9 weeks old, Charles River, U.K.) were
immunised subcutaneously with 105 pfu of vaccine strain
TC-83. On days 14 and 21, mice were immunised subcu-
taneously with a mixture of VEEV strains (TrD, P676,
3880, Mena II, 78V, Fe37c, BeAn8, Pixuna, CaAr508 and
AG80; subtypes IA/B, IC, ID, IE, IF, II, IIIA, IV, V and VI
respectively), totalling approximately 106LD50 (approxi-
mately 106 pfu). Serum samples were taken from the mar-
ginal tail vein on day 28 and assayed for an anti-VEEV
polyclonal response by ELISA with β propiolactone-inac-
tivated TC-83 antigen [15]. Spleens from five immune
mice were removed and processed to extract RNA (TRIzol®
Reagent, Invitrogen, U.K.) which was then converted to
cDNA (SuperScript® III Reverse Transcriptase, Invitrogen).
Antibody heavy- and light-chain-specific primers were
used in a PCR reaction to generate pools of heavy- and
light-chain DNA from the cDNA template [16]. Single
chain VL-Linker-VH constructs (scFv) were then produced
using overlap extension PCR with specific single chain
primers incorporating a linker region [16]. Purified single
chain DNA was digested (Sfi I; New England Biolabs,
U.S.A.) and ligated into pAK100 vector [17]. Phagemids
were electroporated into E.coli  XL1-Blue (Stratagene,
U.S.A.) to produce a library of unique clones. Specificity
of the library was increased by two rounds of biopanning
CUF37-2a reacts with the VEEV E2 glycoprotein Figure 4
CUF37-2a reacts with the VEEV E2 glycoprotein. HEK 293 cells were transfected with plasmids expressing either the 
E2 or E1 glycoprotein of VEEV. 48 h later, the cells were fixed and reacted with 10 μg/ml CUF37-2a, 1A3B7 (E2-specific) or 
3B2A9 (E1-specific) followed by anti-mouse IgG-FITC. The first two columns show representative fields of view under UV illu-
mination. The third column shows identical brightfield views of negative UV-illuminated views.
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[18] against β propiolactone-inactivated antigen from
strain TC-83. Single colonies were isolated from stock
obtained from the second round of panning and phage
supernatants produced from these clones were assayed by
ELISA with β propiolactone-inactivated TC-83 antigen
and HRP-conjugated mouse anti-phage M13 (Amersham
Pharmacia Biotech, U.K.) as the secondary antibody.
Absorbance values greater than twice the background level
were deemed to be positive. The scFv gene fragments from
the positive phagemid clones were amplified using PCR
and initially assessed for uniqueness by analysing restric-
tion digest patterns (BstN I; New England Biolabs,
U.S.A.). Those clones regarded as unique were analysed by
DNA sequencing and compared at the amino acid level
for homology. The supernatants from six phagemid
clones, containing equivalent bacteriophage titres, were
chosen for analysis by ELISA using sucrose density gradi-
ent-purified antigen from multiple VEEV strains (TrD,
P676, 3880, Mena II, 78V, Fe37c, BeAn8, Pixuna,
CaAr508 and AG80) and HRP-conjugated mouse anti-
phage M13 as the secondary antibody. The scFv from the
clone exhibiting the strongest, most wide-ranging
response was converted into a full murine IgG2a kappa
antibody (Haptogen, U.K.). This novel antibody was des-
ignated CUF37-2a and a purified stock of the antibody
was supplied by Haptogen.
Testing the activity of CUF37-2a in vitro
The ability of CUF37-2a (20 μg/ml) to recognise a variety
of VEEV strains was tested by ELISA using sucrose density
gradient-purified antigen from strains TrD, P676, 3880,
Mena II, 78V, Fe37c, BeAn8, Pixuna, CaAr508 and AG80.
So that the reactivity could be meaningfully compared,
the VEEV antigens used in the ELISA were first examined
by SDS-PAGE and scanning densitometry. Each antigen
was diluted in coating buffer to contain an equivalent
CUF37-2a protects against VEEV disease when administered 24h prior to challenge Figure 5
CUF37-2a protects against VEEV disease when administered 24h prior to challenge. In three independent experi-
ments, Balb/c mice (7-8mice/group) remained untreated or were injected with CUF37-2a (5, 50 or 100 μg) intraperitoneally. 
100LD50 VEEV strain TrD were administered subcutaneously 24h later. After challenge, mice were observed twice daily for 
clinical signs of infection and were culled when appropriate using humane endpoints. *P = 0.0043, **P = 0.0001 and ***P < 
0.0001, Mantel-Maenszel Logrank test.
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amount of virus glycoprotein. The ability of the antibody
to neutralise virus infectivity was also determined.
CUF37-2a (25 μg) was mixed with VEEV strains TrD,
Fe37c or BeAn8 (approximately 100 pfu) and incubated at
4°C overnight. Residual infectious virus was estimated by
plaque assay in L929 cells. A reduction in plaque numbers
(compared to virus control wells) of equal to or greater
than 50% in wells inoculated with the virus plus antibody
mixture was considered indicative of neutralisation.
Assessing the glycoprotein specificity of CUF37-2a
The capacity of CUF37-2a to bind to the VEEV E2 or E1
glycoprotein was determined by immunofluorescence
staining. Plasmids expressing either the E2 or E1 protein
from strain TrD (GenBank accession number J04332)
were constructed by GeneArt (Germany). HEK 293 cells
were transfected with each plasmid using the transfection
reagent Lipofectamine 2000 (Invitrogen, UK), according
to the manufacturer's guidelines. The cells were fixed in
acetone after 48 h and were incubated with 10 μg/ml
CUF37-2a, 1A3B7 (E2-specific monoclonal antibody, a
kind gift of Dr. J.T. Roehrig, Division of Vector-borne
Infectious Diseases, CDC, Fort Collins, Colorado, U.S.A.;
Phillpotts, 2006) or 3B2A9 (E1-specific monoclonal anti-
body, a kind gift of Dr. J.T. Roehrig; Phillpotts, 2006) fol-
lowed by a 1/800 dilution of anti-mouse IgG conjugated
to FITC (Sigma, U.K.) before being examined under UV
illumination.
Determining the in vivo activity of CUF37-2a
The ability of CUF37-2a to protect against a challenge
dose of 100LD50 (approximately 30-50 pfu) VEEV strain
TrD (subtype IA/B) was tested. In three independent
experiments, groups of Balb/c mice (7-9 weeks old,
Charles River, U.K.) remained untreated or were injected
intraperitoneally with 5, 50 or 100 μg of antibody in 50-
100 μl PBS. The challenge virus was administered subcu-
taneously 24 h later. After challenge, mice were observed
twice daily for clinical signs of infection by an independ-
ent observer [15]. Humane endpoints were used and these
experiments therefore record the occurrence of severe dis-
ease rather than mortality [19]. Even though it is rare for
animals infected with virulent VEEV and showing signs of
severe illness to survive, our use of humane endpoints
should be considered when interpreting any virus dose
expressed here as 50% lethal doses (LD50).
Enzyme immunoassay
Mouse sera, harvested by cardiac puncture 14 days after
the challenge dose was administered, were assayed for
VEEV-specific IgG1 antibodies using sucrose density gra-
dient-purified antigen from strain TrD [10]. Immu-
noglobulin concentrations were estimated by comparison
of the absorbance values generated by diluted serum sam-
ples (three replicates) with a standard curve prepared
from dilutions of mouse IgG1 (Sigma, U.K.).
Titration of virus in the brain
The amount of VEEV strain TrD present within mouse
brains was determined by titration on Vero cells. Brains
were removed and homogenised in 2 ml PBS by passing
through a 70 μm nylon cell strainer (BD Falcon, U.K.).
200 μl of the cell suspension were added to each well of
the first column of a 96-well plate and the homogenate
was then serially diluted (1:10) in cell culture media
across the plate. 100 μl of the diluted homogenate from
each well were then added to the corresponding well of a
96-well plate containing confluent monolayers of Vero
cells. The cells were incubated for 72 h after which time
the monolayers were fixed by the addition of 10% (v/v)
formal saline and stained with 0.1% (w/v) crystal violet.
The concentration of VEEV, expressed as 50% tissue cul-
ture infectious doses (TCID50), was calculated by Reed-
Muench analysis of virus-positive wells [20]. The concen-
tration was then converted to pfu by multiplying the
TCID50 value by 0.69 [21].
Statistical methods
Statistical analysis was performed using the Mantel-Maen-
szel Logrank test and GraphPad Prism http://www.graph
pad.com software.
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